Surgery in metastatic testicular cancer

European Urology

Volumn 44, Issue 2, 2003, Pages 233-244

  Albers, Peter ^a,b   Melchior, Diethild ^a   Müller, Stefan C ^a  

^a UNIVERSITY OF BONN   (Germany)

^b KLINIKUM KASSEL   (Germany)

Author keywords

Complications; Germ cell tumor; Lymph node excision; Resection; Testis cancer

Indexed keywords

CANCER SURGERY; FOLLOW UP; GERM CELL TUMOR; HUMAN; LYMPHADENECTOMY; METASTASIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SEMINOMA; SURGICAL TECHNIQUE; TESTIS CANCER; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0042268006     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00252-5     Document Type: Review

References (52)

1. Einhorn LH. Testicular cancer as a model for a curable neoplasm. The Richard and Hinda Rosenthal Foundation Lecture. Cancer Res 1981;41:3275-80.
2. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
3. Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818-26.
4. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569-73.
5. Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997;15:1455-64.
6. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer 1982;50:1629-35.
7. Donohue JP, Fox EP, Williams SD, Loehrer PJ, Ulbright TM, Einhorn LH, et al. Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 1994;12:190-5.
8. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001;19:2647-57.
9. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177-87.
10. Albers P, Weinknecht S, Krege S, Kliesch S, Hartmann M, Heidenreich A, et al. Prediction of necrosis after chemotherapy of advanced germ-cell-tumors - results of a prospective multicenter trial of the GTCSG. J Urol 2002;167(Suppl):172.
11. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer, ReHiT Study Group. Int J Cancer 1999;83:856-9.
12. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000;164:381-4.
13. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43:74-80.
14. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11:324-9.
15. Flechon A, Rivoire M, Biron P, Droz JP. Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors. J Urol 2001;165:1920-6.
16. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 1998;81:884-8.
17. Wood Jr DP, Herr HW, Motzer RJ, Reuter V, Sogani PC, Morse MJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 1992;70:2354-7.
18. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhom LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
19. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997;8:41-7.
20. Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860-2.
21. Motzer RJ, Bosl GJ, Geller NL, Penenberg D, Yagoda A, Golbey R, et al. Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med 1988;108:513-8.
22. Schultz SM, Einhom LH, Conces Jr DJ, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989;7:1497-503.
23. Sheinfeld J, Herr HW. Role of surgery in management of germ cell tumor. Semin Oncol 1998;25:203-9.
24. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, et al. Predictive impact of 2-18fluoro -2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740-4.
25. Mosharafa AA, Foster RS, Leibovitch BC. Is the post chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2002;167(Suppl):172.
26. Steyerberg EW, Donohue JP, Gerl A, Toner GC, Schraffordt Koops H, Fossa SD, et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Reanalysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 1997;158:474-8.
27. Gerl A, Clemm C, Schmeller N, Dienemann H, Weiss M, Kriegmair M, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994;70:960-5.
28. Locatelli MC, Tedeschi L, Clerici M, Romanelli A, D'Antona A, Labianca R, et al. Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration. Support Care Cancer 1996;4:218-9.
29. Albers P, Heicappell R, Schwaibold H, Wolff J. Erythropoetin in urologic oncology. Eur Urol 2001;39:1-8.
30. Albers P. Retroperitoneale Residualtumorresektion nach Chemotherapie maligner Hodentumoren. Aktuel Urol 2001;32:147-54.
31. Foster RS, Donohue JP, Albers P, Voges E. Retroperitoneale Lymphadenektomie (RPLA) - Nervenerhaltende Operationstechnik. Aktuel Urol 1993;24:I-X.
32. Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am 1977;4:509-21.
33. Donohue JP, Rowland RG, Bihrle RG. Transabdominal retroperitoneal lymph node dissection. In: Skinner DG, Lieskovsky G, Herausgeber. Diagnosis and Management of Genitourinary Cancer. Philadelphia: W.B. Saunders; 1988. p. 802-916.
34. Leibovitch I, Nash PA, Little Jr JS, Foster RS, Donohue JP. Spinal cord ischemia after post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell cancer. J Urol 1996;155:947-51.
35. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995;153:976-80.
36. Nash PA, Leibovitch I, Foster RS, Bihrle R, Rowland RG, Donohue JP. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol 1998;159:707-10.
37. Donohue JP, Thornhill JA, Foster RS, Bihrle R. Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part II. World J Urol 1994;12:187-9.
38. Ahlering TE, Skinner DG. Vena caval resection in bulky metastatic germ cell tumors. J Urol 1989;142:1497-9.
39. Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg 1998;28:808-14.
40. Christmas TJ, Smith GL, Kooner R. Vascular interventions during post-chemotherapy retroperitoneal lymph-node dissection for metastatic testis cancer. Eur J Surg Oncol 1998;24:292-7.
41. Donohue JP, Thornhill JA, Foster RS, Bihrle R. Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part I - Vena cava. World J Urol 1994;12:182-6.
42. Husband JE, Bellamy EA. Unusual thoracoabdominal sites of metastases in testicular tumors. AJR Am J Roentgenol 1985;145:1165-71.
43. Mullen JC, Lemermeyer G, Tittley J, Ameli FM, Lossing AG, Jewett MA. Metastatic testicular tumor requiring inferior vena cava resection. Urology 1996;47:263-5.
44. Spitz A, Wilson TG, Kawachi MH, Ahlering TE, Skinner DG. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. J Urol 1997;158:1813-8.
45. Kelly R, Skinner D, Yellin AE, Weavr FA. En bloc aortic resection for bulky metastatic germ cell tumors. J Urol 1995;156:1849-51.
46. Christmas TJ, Smith GL, Kooner RS. Wedge resection of pulmonary metastases from cancer of the testis or kidney using a vascular staple device. Br J Urol 1998;81:911-2.
47. Goulet Jr RJ, Hardacre JM, Einhom LH, Loehrer PJ, Jones JA, Donohue JP, et al. Hepatic resection for disseminated germ cell carcinoma. Ann Surg 1990;212:290-3 [Discussion 293-294].
48. Donohue JP, Rowland RG. Complications of retroperitoneal lymph node dissection. J Urol 1981;125:338-40.
49. Skinner DG, Melamud A, Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymph node dissection. J Urol 1982;127:1107-10.
50. Waid-Jones MI, Coursin DB. Perioperative considerations for patients treated with bleomycin. Chest 1991;99:993-9.
51. Goldiner PL, Schweizer O. The hazards of anesthesia and surgery in bleomycin-treated patients. Semin Oncol 1979;6:121-4.
52. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer. J Urol 1993;150:1422-4.